(NYSE: MRK) Merck & Co's forecast annual revenue growth rate of 6.34% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Merck & Co's revenue in 2024 is $61,402,000,000.On average, 6 Wall Street analysts forecast MRK's revenue for 2024 to be $163,113,252,994,512, with the lowest MRK revenue forecast at $162,150,158,461,888, and the highest MRK revenue forecast at $164,633,096,345,509. On average, 7 Wall Street analysts forecast MRK's revenue for 2025 to be $174,597,429,900,328, with the lowest MRK revenue forecast at $168,294,478,085,201, and the highest MRK revenue forecast at $182,151,831,180,519.
In 2026, MRK is forecast to generate $187,221,762,229,272 in revenue, with the lowest revenue forecast at $175,842,772,769,386 and the highest revenue forecast at $204,113,794,668,516.